Am. J. Respir. Crit. Care Med., Volume 160, Number 1, July 1999, 192-197

Randomized Trial of Prolonged Chloroquine Therapy in Advanced Pulmonary Sarcoidosis

MARCEL BALTZAN, SANJAY MEHTA, TREVOR H. KIRKHAM, and MANUEL G. COSIO

Respiratory Division and the Division of Neuro-Ophthalmology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada

Sarcoidosis may cause severe ventilatory impairment requiring corticosteroid treatment. Chloroquine (CQ) can be an effective treatment for lung sarcoidosis with few side effects, but has not been accepted as standard therapy. We investigated the benefits of prolonged CQ therapy in 23 symptomatic patients with biopsy-proven pulmonary sarcoidosis (duration,  2 yr). Patients were initially treated for 6 mo with CQ, 750 mg/d, tapering every 2 mo to 250 mg/d. Eighteen patients were then randomized to either a Maintenance group (CQ, 250 mg/d) or to an Observation group (no CQ). After the initial treatment, significant improvement was observed in symptoms, pulmonary function, angiotensin-converting enzyme, and lung gallium scan. Patients randomized to the Maintenance group showed a slower decline in pulmonary function (FEV₁, 51.4 ± 28.2 ml/yr [Maintenance] versus 196.3 ± 33.4 ml/yr [Observation], p < 0.02) and had fewer relapses: 2 of 10 patients in the Maintenance group at 29.5 ± 4.9 mo versus 6 of 8 patients in the Observation group at 15.5 ± 2.9 mo. Adverse effects were seen mainly during high-CQ dosage. We conclude that CQ should be an important consideration for the treatment and maintenance of chronic pulmonary sarcoidosis.

This article has been cited by other articles:

				A U Wells, N Hirani, and on behalf of the British Thoracic Society Intersti Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society Thorax, September 1, 2008; 63(Suppl_V): v1 - v58. [Full Text] [PDF]

				M. Mahevas, S. Audia, V. De Lastours, M. Michel, B. Bonotte, and B. Godeau Neutropenia in Felty's syndrome successfully treated with hydroxychloroquine Haematologica, July 1, 2007; 92(7): e78 - e79. [Full Text] [PDF]

				S. E. Weinberger A 47-year-old woman with sarcoidosis. JAMA, November 1, 2006; 296(17): 2133 - 2140. [Abstract] [Full Text] [PDF]

				J. C. Grutters and J. M. M. van den Bosch Corticosteroid treatment in sarcoidosis. Eur. Respir. J., September 1, 2006; 28(3): 627 - 636. [Abstract] [Full Text] [PDF]

				Y. S. Wasfi, C. S. Rose, J. R. Murphy, L. J. Silveira, J. C. Grutters, Y. Inoue, M. A. Judson, and L. A. Maier A New Tool To Assess Sarcoidosis Severity Chest, May 1, 2006; 129(5): 1234 - 1245. [Abstract] [Full Text] [PDF]

				V. Majithia, S. Sanders, V. Harisdangkul, and J. G. Wilson Successful treatment of sarcoidosis with leflunomide Rheumatology, May 1, 2003; 42(5): 700 - 702. [Full Text] [PDF]

				U. Costabel Sarcoidosis: clinical update Eur. Respir. J., July 1, 2001; 18(32_suppl): 56S - 68s. [Abstract] [Full Text] [PDF]

				G J GIBSON Sarcoidosis: old and new treatments Thorax, May 1, 2001; 56(5): 336 - 339. [Full Text]

				A ROTHOVA Ocular involvement in sarcoidosis Br. J. Ophthalmol., January 1, 2000; 84(1): 110 - 116. [Full Text]